Clinical Trial Update: A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms [Phase 2]

View source ↗

Summary

Phase 2 study of RO6889450 (Ralmitaront) in schizophrenia or schizoaffective disorder with negative symptoms was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Ralmitaront (RO6889450) (Ralmitaront)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: TERMINATED | Results posted: 2024-08-12